mRNA-based cancer therapeutics

C Liu, Q Shi, X Huang, S Koo, N Kong, W Tao - Nature Reviews Cancer, 2023 - nature.com
Due to the fact that mRNA technology allows the production of diverse vaccines and
treatments in a shorter time frame and with reduced expense compared to conventional …

Advances in antibody-based therapy in oncology

S Zinn, R Vazquez-Lombardi, C Zimmermann, P Sapra… - Nature Cancer, 2023 - nature.com
Monoclonal antibodies are a growing class of targeted cancer therapeutics, characterized by
exquisite specificity, long serum half-life, high affinity and immune effector functions. In this …

Emerging principles of cytokine pharmacology and therapeutics

RA Saxton, CR Glassman, KC Garcia - Nature Reviews Drug Discovery, 2023 - nature.com
Cytokines are secreted signalling proteins that play essential roles in the initiation,
maintenance and resolution of immune responses. Although the unique ability of cytokines …

A split, conditionally active mimetic of IL-2 reduces the toxicity of systemic cytokine therapy

A Quijano-Rubio, AM Bhuiyan, H Yang, I Leung… - Nature …, 2023 - nature.com
The therapeutic potential of recombinant cytokines has been limited by the severe side
effects of systemic administration. We describe a strategy to reduce the dose-limiting …

Strategies to therapeutically modulate cytokine action

WJ Leonard, JX Lin - Nature Reviews Drug Discovery, 2023 - nature.com
Cytokines are secreted or membrane-presented molecules that mediate broad cellular
functions, including development, differentiation, growth and survival. Accordingly, the …

Reprogramming systemic and local immune function to empower immunotherapy against glioblastoma

S Zhou, Y Huang, Y Chen, Y Liu, L Xie, Y You… - Nature …, 2023 - nature.com
The limited benefits of immunotherapy against glioblastoma (GBM) is closely related to the
paucity of T cells in brain tumor bed. Both systemic and local immunosuppression contribute …

Immunotherapy for metastatic triple negative breast cancer: current paradigm and future approaches

V Geurts, M Kok - Current Treatment Options in Oncology, 2023 - Springer
Opinion statement In approximately 15–20% of the patients diagnosed with breast cancer, it
comprises the triple negative (TN) subtype, which until recently lacked targets for specific …

Alum-anchored intratumoral retention improves the tolerability and antitumor efficacy of type I interferon therapies

EA Lutz, Y Agarwal, N Momin… - Proceedings of the …, 2022 - National Acad Sciences
Effective antitumor immunity in mice requires activation of the type I interferon (IFN)
response pathway. IFNα and IFNβ therapies have proven promising in humans, but suffer …

Extracellular vesicle–based drug delivery in cancer immunotherapy

S Najafi, J Majidpoor, K Mortezaee - Drug Delivery and Translational …, 2023 - Springer
Extracellular vesicles (EVs) are a group of nanoscale membrane-bound organelles
including exosomes, microvesicles (MVs), membrane particles, and apoptotic bodies, which …

Nadofaragene firadenovec: First approval

A Lee - Drugs, 2023 - Springer
Nadofaragene firadenovec (nadofaragene firadenovec-vncg; Adstiladrin®) is a non-
replicating adenoviral vector-based gene therapy developed by Ferring Pharmaceuticals for …